Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Sex-specific associations between metabolic hormones, severe mental disorders and antipsychotic treatment
Psychoneuroendocrinology, 146, 105927 (in press)
High prevalence and significant ethnic differences in actionable HbA1C after gestational diabetes mellitus in women living in Norway
BMC Med, 20 (1), 318
Changes in cardiopulmonary exercise capacity and limitations 3 to 12 months after COVID-19
Eur Respir J (in press)